EPO

EPO, or Erythropoietin, is a glycoprotein hormone that serves as the primary regulator of red blood cell production (erythropoiesis) in the human body. Produced mainly by the kidneys, EPO travels to the bone marrow, where it stimulates the differentiation and proliferation of red blood cell precursors. This increase in red blood cell mass enhances the oxygen-carrying capacity of the blood, making it a critical subject of research for treating anemia associated with chronic kidney disease, chemotherapy, and other medical conditions. In the context of sports science and performance research, EPO is studied for its ability to significantly improve aerobic capacity and endurance.

In addition to its hematological functions, modern research has identified EPO as a multifaceted cytoprotective agent. It has been found to have neuroprotective and cardioprotective properties, helping to safeguard cells from damage caused by hypoxia (low oxygen), oxidative stress, and inflammation. Scientists are currently exploring the use of EPO in the recovery from stroke, traumatic brain injury, and myocardial infarction. This product is synthesized to the highest pharmaceutical-grade standards, providing researchers with a reliable model to study the complex signaling pathways involved in tissue oxygenation, cellular survival, and the systemic regulation of blood oxygen levels.